Ana Laura Fitas1, Catarina Martins2, Luís Miguel Borrego2, Lurdes Lopes1, Anne Jörns3, Sigurd Lenzen3,4, Catarina Limbert1. 1. Paediatric Endocrinology Unit, Hospital de Dona Estefânia, Centro Hospitalar de Lisboa Central, Lisbon, Portugal. 2. Chronic Diseases Research Center CEDOC-NOVA Medical School, Lisbon, Portugal. 3. Institute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany. 4. Institute of Experimental Diabetes Research, Hannover Medical School, Hannover, Germany.
Abstract
OBJECTIVE: Type 1 diabetes (T1D) develops in distinct stages, before and after disease onset. Whether the natural course translates into different immunologic patterns is still uncertain. This study aimed at identifying peripheral immune patterns at key time-points, in T1D children undergoing remission phase. METHODS: Children with new-onset T1D and healthy age and gender-matched controls were recruited at a pediatric hospital. Peripheral blood samples were evaluated by flow cytometry at 3 longitudinal time-points: onset (T1), remission phase (T2) and established disease (T3). Cytokine levels were quantified by multiplex assay. Fasting C-peptide, HbA1c, and 25OHD were also measured. RESULTS: T1D children (n = 28; 10.0 ± 2.6 years) showed significant differences from controls in circulating neutrophils, T helper (Th)17 and natural killer (NK) cells, with relevant variations during disease progression. At onset, neutrophils, NK, Th17 and T cytotoxic (Tc)17 cells were decreased. As disease progressed, neutrophil counts recovered whereas NK counts remained low. Th17 and Tc17 cells behavior followed the neutrophil variation pattern. B-cells were lowest in the remission phase and regulatory T-cells significantly declined after remission. Two cytokine response profiles were identified. Low cytokine-responders showed higher circulating fasting C-peptide levels at onset and longer remission periods. C-peptide inversely correlated with pro-inflammatory and cytotoxic cells. CONCLUSIONS: Our data suggest an association between immune cells, cytokine patterns and metabolic counterparts. The dynamic changes of circulating immune cells during disease progression involve key innate and acquired immune cell types. This longitudinal picture of T1D progression may enable disease staging and patient stratification, essential for individualized treatment.
OBJECTIVE:Type 1 diabetes (T1D) develops in distinct stages, before and after disease onset. Whether the natural course translates into different immunologic patterns is still uncertain. This study aimed at identifying peripheral immune patterns at key time-points, in T1D children undergoing remission phase. METHODS:Children with new-onset T1D and healthy age and gender-matched controls were recruited at a pediatric hospital. Peripheral blood samples were evaluated by flow cytometry at 3 longitudinal time-points: onset (T1), remission phase (T2) and established disease (T3). Cytokine levels were quantified by multiplex assay. Fasting C-peptide, HbA1c, and 25OHD were also measured. RESULTS: T1D children (n = 28; 10.0 ± 2.6 years) showed significant differences from controls in circulating neutrophils, T helper (Th)17 and natural killer (NK) cells, with relevant variations during disease progression. At onset, neutrophils, NK, Th17 and T cytotoxic (Tc)17 cells were decreased. As disease progressed, neutrophil counts recovered whereas NK counts remained low. Th17 and Tc17 cells behavior followed the neutrophil variation pattern. B-cells were lowest in the remission phase and regulatory T-cells significantly declined after remission. Two cytokine response profiles were identified. Low cytokine-responders showed higher circulating fasting C-peptide levels at onset and longer remission periods. C-peptide inversely correlated with pro-inflammatory and cytotoxic cells. CONCLUSIONS: Our data suggest an association between immune cells, cytokine patterns and metabolic counterparts. The dynamic changes of circulating immune cells during disease progression involve key innate and acquired immune cell types. This longitudinal picture of T1D progression may enable disease staging and patient stratification, essential for individualized treatment.
Authors: Laia Gomez-Muñoz; David Perna-Barrull; Adrian Villalba; Silvia Rodriguez-Fernandez; Rosa-Maria Ampudia; Aina Teniente-Serra; Federico Vazquez; Marta Murillo; Jacobo Perez; Raquel Corripio; Joan Bel; Marta Vives-Pi Journal: Front Immunol Date: 2021-01-25 Impact factor: 7.561
Authors: Laia Gomez-Muñoz; David Perna-Barrull; Josep M Caroz-Armayones; Marta Murillo; Silvia Rodriguez-Fernandez; Aina Valls; Federico Vazquez; Jacobo Perez; Raquel Corripio; Luis Castaño; Joan Bel; Marta Vives-Pi Journal: Front Immunol Date: 2022-02-23 Impact factor: 7.561
Authors: Aleksandra Starosz; Milena Jamiołkowska-Sztabkowska; Barbara Głowińska-Olszewska; Marcin Moniuszko; Artur Bossowski; Kamil Grubczak Journal: Front Immunol Date: 2022-08-24 Impact factor: 8.786
Authors: Silvia Garavelli; Sara Bruzzaniti; Elena Tagliabue; Francesco Prattichizzo; Dario Di Silvestre; Francesco Perna; Lucia La Sala; Antonio Ceriello; Enza Mozzillo; Valentina Fattorusso; Pierluigi Mauri; Annibale A Puca; Adriana Franzese; Giuseppe Matarese; Mario Galgani; Paola de Candia Journal: Int J Mol Sci Date: 2020-01-11 Impact factor: 5.923